AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Ignalis-M 100/1000 Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (100mg) + Metformin (1000mg)

Overview Ignalis-M 100/1000 Tablet ER

Dia-Dual 100/1000 Extended-Release tablets combine two medications to manage elevated blood glucose in type 2 diabetes patients. This dual action helps prevent severe diabetic complications like kidney failure and vision loss, potentially lowering heart attack and stroke risks. Dia-Dual 100/1000 ER may be used alone or with other diabetes treatments. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health, blood sugar readings, and current medications. Consuming it with food minimizes stomach upset. Consistent daily dosing, at the same time, maximizes effectiveness; discontinue only under physician guidance. Adherence to your prescribed diet and exercise plan is crucial for successful diabetes control; lifestyle significantly impacts management. Common side effects include diarrhea, nausea, vomiting, indigestion, headache, and throat irritation. Low blood sugar (hypoglycemia) is a potential side effect when used with insulin or sulfonylureas; learn hypoglycemia recognition and treatment. This medication isn't for everyone. Inform your physician of any history of kidney, liver, or heart disease, pancreatic issues, or significant alcohol consumption before starting. Pregnant or nursing individuals require medical consultation prior to use. Interactions with other drugs are possible; disclose all medications to ensure safety. Alcohol should be minimized due to its blood sugar-lowering effect. Your doctor will monitor kidney function and glucose levels throughout treatment.

Uses of Ignalis-M 100/1000 Tablet ER

Managing type 2 diabetes

Major Benefits of Ignalis-M 100/1000 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing it. It is recommended to take Ignalis-M 100/1000 Extended-Release tablets with a meal.

Common Side effects of Ignalis-M 100/1000 Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Ignalis-M 100/1000 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the Ignalis-M 100/1000 Tablet ER whole; avoid chewing, crushing, or fracturing it. Administer this extended-release tablet with a meal.

How Ignalis-M 100/1000 Tablet ER works:

Ignalis-M 100/1000 Extended-Release tablets combine sitagliptin and metformin to manage blood glucose levels. Sitagliptin boosts insulin production by the pancreas, enhances insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin responsiveness. This dual action promotes superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Ignalis-M 100/1000 Tablet ER and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Ignalis-M 100/1000 tablets might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against potential hazards prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Ignalis-M 100/1000 tablets are likely unsafe for breastfeeding mothers. Preliminary human data indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.

KidneyKidneyCAUTION

Patients with kidney impairment should use Ignalis-M 100/1000 Tablet ER cautiously, potentially requiring dosage modification. Consult a physician for guidance. Ignalis-M 100/1000 Tablet ER is contraindicated in those with severe kidney disease. Close monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

Extended-release Ignalis-M 100/1000 tablets pose a likely risk for individuals with hepatic impairment and are best avoided. Medical advice is recommended.

What if you forget to take Ignalis-M 100/1000 Tablet ER :

Should you forget a dose of Ignalis-M 100/1000 Extended-Release Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Ignalis-M 100/1000 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Ignalis-M 100/1000 Tablet ER

Ignalis-M 100/1000 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Ignalis-M 100/1000 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia and neurological issues, including numbness and tingling in the extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Ignalis-M 100/1000 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 100/1000 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 100/1000 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, as directed on the label. Dispose of any unused medication safely and prevent access by children, pets, and others.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Ignalis-M 100/1000 Tablet ER. This rare complication is avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms may include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, or bradycardia. If these symptoms occur, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Ignalis-M 100/1000 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This combination is not suitable for individuals under 18.
Ignalis-M 100/1000 Tablet ER may cause common side effects including low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis are possible. Prolonged use may also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 100/1000 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 100/1000 Tablet ER and alcohol is unsafe and may raise the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Ignalis-M 100/1000 Tablet ER. This is due to a buildup of lactic acid in the blood and is rare, but avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms may include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, or bradycardia. If these symptoms occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Ignalis-M 100/1000 Tablet ER use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Ignalis-M 100/1000 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Ignalis-M 100/1000 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 100/1000 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 100/1000 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA when linked to metformin), is a potential side effect of Ignalis-M 100/1000 Tablet ER. This rare complication is avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Ignalis-M 100/1000 Tablet ER use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication; keep it out of reach of children, pets, and others.
Ignalis-M 100/1000 Tablet...
141
MRP 164
13% off